当前位置：
文档之家› 利妥昔单抗、利那度胺、依鲁替尼联合化疗治疗ne患者疗效确切
利妥昔单抗、利那度胺、依鲁替尼联合化疗治疗ne患者疗效确切
Presented By Jason Westin at 2019 ASCO Annual Meeting
Survival
Presented By Jason Westin at 2019 ASCO Annual Meeting
Double Expressor
Presented By Jason Westin at 2019 ASCO Annual Meeting
Conclusions
Presented By Jason Westin at 2019 ASCO Annual Meeting
Conclusions
Presented By Jason Westin at 2019 ASCO Annual Meeting
Acknowledgements
Presented By Jason Westin at 2019 ASCO Annual Meeting
Adverse Events idenented By Jason Westin at 2019 ASCO Annual Meeting
Smart Start: <br />CNS Aspergillosis (n=1)
Presented By Jason Westin at 2019 ASCO Annual Meeting
Slide 11
Presented By Jason Westin at 2019 ASCO Annual Meeting
Disease burden change
Presented By Jason Westin at 2019 ASCO Annual Meeting
Smart Start: <br />PR after RLI 2 cycles (n = 29, 50%)<br />
Presented By Jason Westin at 2019 ASCO Annual Meeting
Background
Presented By Jason Westin at 2019 ASCO Annual Meeting
Previous DLBCL studies
Presented By Jason Westin at 2019 ASCO Annual Meeting
Abstract 7508: <br />Smart Start: Final results of rituximab, lenalidomide, and ibrutinib lead in prior to combination with chemotherapy for patients with newly diagnosed diffuse large B-cell lymphoma
Rationale
Presented By Jason Westin at 2019 ASCO Annual Meeting
Synthetic Lethality of Lenalidomide and Ibrutinib
Presented By Jason Westin at 2019 ASCO Annual Meeting
Presented By Jason Westin at 2019 ASCO Annual Meeting
Smart Start: <br />RLI alone (n = 1)
Presented By Jason Westin at 2019 ASCO Annual Meeting
Smart Start: <br />PR after end of therapy (n = 2)
Study Design
Presented By Jason Westin at 2019 ASCO Annual Meeting
Results
Presented By Jason Westin at 2019 ASCO Annual Meeting
Therapy Received
Presented By Jason Westin at 2019 ASCO Annual Meeting
